Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

BACKGROUND: We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial (NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for metastatic disease. PATIENTS AND METHODS: Patients received avelumab (10 mg/kg)—a human anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Keilholz, Ulrich, Mehnert, Janice M., Bauer, Sebastian, Bourgeois, Hugues, Patel, Manish R., Gravenor, Donald, Nemunaitis, John J., Taylor, Matthew H., Wyrwicz, Lucjan, Lee, Keun-Wook, Kasturi, Vijay, Chin, Kevin, von Heydebreck, Anja, Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335739/
https://www.ncbi.nlm.nih.gov/pubmed/30651126
http://dx.doi.org/10.1186/s40425-018-0459-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335739/
https://www.ncbi.nlm.nih.gov/pubmed/30651126
http://dx.doi.org/10.1186/s40425-018-0459-y

Ejemplares similares